Cross-Sectional Survey of Real-World Physician Prescribing Practices for Anti-VEGF Agents in the Treatment of Neovascular Age-Related Macular Degeneration and Associated Patient Burden in the United States

Despite receiving treatment, nAMD patients have substantial remaining symptom and treatment burden. Physicians may choose faricimab over purely anti-VEGF agents for its clinical efficacy and reduced treatment burden. Physicians take both clinical factors and patient burden into account when selecting agents and dosing regimens, while reimbursement concerns hinder prescribing in some patients.